Eka Ventures Raises $107 Million for Second Impact Fund, Becomes UK’s Largest Early‑Stage ESG VC

Why It Matters

Eka Ventures’ $107 million close demonstrates that impact‑oriented venture capital can attract substantial capital at scale, challenging the perception that ESG funds must sacrifice returns for purpose. By aggregating public‑interest and philanthropic capital, the fund validates a growing consensus among limited partners that early‑stage impact investments can deliver both financial and societal value. The fund also highlights a strategic shift in UK venture capital toward consumer‑facing sustainability and preventative health solutions, sectors traditionally under‑funded by conventional VCs. If Eka’s portfolio achieves its projected DPI and TVPI performance, it could set a benchmark for future impact funds, prompting larger institutional investors to allocate more to early‑stage ESG ventures and potentially reshaping the capital distribution across Europe’s startup ecosystem.

Key Takeaways

• Eka Ventures closed its second fund at $107 million (£80 million), the largest early‑stage impact VC fund in the UK.
• Total assets under management now stand at $200 million.
• Fund II will back up to 30 pre‑seed/seed UK startups with an average first cheque of $2 million.
• LP base includes British Business Bank (£36 million commitment to Fund I) and several major foundations.
• Eka claims its first fund ranks in the top 5% of its 2021 vintage for DPI and TVPI.

Pulse Analysis

Eka Ventures’ fundraising success arrives at a moment when European LPs are recalibrating their exposure to climate and health‑tech. The firm’s ability to marshal $107 million from a mix of public‑interest and philanthropic sources suggests that impact capital is no longer a niche allocation but a mainstream component of diversified portfolios. This shift mirrors broader trends in the United States, where impact‑focused funds have begun to rival traditional VC raises, and it could accelerate cross‑border capital flows into UK‑based startups.

Historically, UK venture capital has been dominated by technology and fintech, with relatively modest activity in consumer‑impact sectors. Eka’s thesis—targeting the intersection of preventative health, sustainable consumption and essential services—leverages a structural inefficiency in public spending: the gap between treatment and prevention. By quantifying that gap (5.2% of NHS spending on prevention versus 10.9% of GDP on health overall), Eka provides a data‑driven investment thesis that resonates with both impact‑driven and financially motivated LPs. If the fund’s portfolio can demonstrate measurable health outcomes and carbon‑reduction metrics, it will set a precedent for impact‑reporting standards that could become a de‑facto requirement for future ESG funds.

Looking forward, the real test will be deployment speed and follow‑on success. Eka’s commitment to lead or co‑lead 90% of deals gives it control over capital allocation, but it also concentrates risk. The firm’s AI‑backed sourcing platform could provide a competitive edge in identifying high‑potential startups before they enter the radar of larger VCs. Should Eka achieve its target returns while delivering quantifiable societal impact, it will likely inspire a new wave of impact‑first funds across Europe, prompting incumbents to either partner with or acquire such niche players to stay relevant in an increasingly purpose‑driven investment landscape.